Atrinsic (PTIX) Competitors $3.22 +0.17 (+5.57%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$3.20 -0.03 (-0.78%) As of 10/17/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PTIX vs. ALZN, SNGX, KZIA, PMCB, PLRZ, QLGN, SNOA, PBM, NLSP, and CPHIShould you be buying Atrinsic stock or one of its competitors? The main competitors of Atrinsic include Alzamend Neuro (ALZN), Soligenix (SNGX), Novogen (KZIA), Nuvilex (PMCB), Polyrizon (PLRZ), Qualigen Therapeutics (QLGN), Sonoma Pharmaceuticals (SNOA), Psyence Biomedical (PBM), NLS Pharmaceutics (NLSP), and China Pharma (CPHI). These companies are all part of the "pharmaceutical products" industry. Atrinsic vs. Its Competitors Alzamend Neuro Soligenix Novogen Nuvilex Polyrizon Qualigen Therapeutics Sonoma Pharmaceuticals Psyence Biomedical NLS Pharmaceutics China Pharma Atrinsic (NASDAQ:PTIX) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership. Which has more risk & volatility, PTIX or ALZN? Atrinsic has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500. Do institutionals and insiders hold more shares of PTIX or ALZN? 8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 35.0% of Atrinsic shares are owned by company insiders. Comparatively, 30.2% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is PTIX or ALZN more profitable? Alzamend Neuro's return on equity of -151.24% beat Atrinsic's return on equity.Company Net Margins Return on Equity Return on Assets AtrinsicN/A -1,586.63% -585.65% Alzamend Neuro N/A -151.24%-124.17% Do analysts recommend PTIX or ALZN? Alzamend Neuro has a consensus price target of $42.00, suggesting a potential upside of 1,791.89%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Atrinsic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to PTIX or ALZN? In the previous week, Alzamend Neuro had 4 more articles in the media than Atrinsic. MarketBeat recorded 4 mentions for Alzamend Neuro and 0 mentions for Atrinsic. Atrinsic's average media sentiment score of 0.00 beat Alzamend Neuro's score of -0.20 indicating that Atrinsic is being referred to more favorably in the media. Company Overall Sentiment Atrinsic Neutral Alzamend Neuro Neutral Which has better valuation and earnings, PTIX or ALZN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtrinsicN/AN/A-$5.53M-$9.44-0.34Alzamend NeuroN/AN/A-$4.51MN/AN/A SummaryAlzamend Neuro beats Atrinsic on 8 of the 11 factors compared between the two stocks. Get Atrinsic News Delivered to You Automatically Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTIX vs. The Competition Export to ExcelMetricAtrinsicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.80M$3.39B$6.09B$10.49BDividend YieldN/A2.28%5.73%4.80%P/E Ratio-0.3422.5884.9827.13Price / SalesN/A267.64519.68179.70Price / CashN/A46.5937.1661.22Price / Book1.6410.4112.236.52Net Income-$5.53M-$52.47M$3.33B$276.93M7 Day Performance-3.88%2.31%1.18%1.94%1 Month Performance-15.93%11.13%6.16%2.20%1 Year Performance-58.04%11.12%60.00%35.02% Atrinsic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTIXAtrinsic0.1772 of 5 stars$3.22+5.6%N/A-57.4%$1.80MN/A-0.342Gap DownALZNAlzamend Neuro2.2406 of 5 stars$2.24+1.6%$42.00+1,778.4%-85.0%$7.08MN/A0.004News CoverageAnalyst ForecastShort Interest ↑SNGXSoligenix2.4564 of 5 stars$1.65-4.4%$6.00+264.7%-54.5%$7.06M$120K-0.4320Gap DownKZIANovogen3.89 of 5 stars$6.96+2.2%$16.50+137.1%-73.4%$7.03M$1.51M0.0012Positive NewsShort Interest ↓PMCBNuvilex0.0815 of 5 stars$1.03+2.9%N/A-43.0%$7.00MN/A-1.914Short Interest ↑High Trading VolumePLRZPolyrizonN/A$1.16-1.7%N/AN/A$6.95MN/A0.00N/APositive NewsShort Interest ↓Gap DownQLGNQualigen TherapeuticsN/A$3.93-2.1%N/A-54.6%$6.65M$4.98M0.0050Short Interest ↑SNOASonoma Pharmaceuticals1.0902 of 5 stars$4.00-1.8%N/A+30.7%$6.61M$14.29M-1.64180News CoveragePBMPsyence Biomedical0.5676 of 5 stars$3.41-4.2%N/A-94.8%$6.38MN/A0.00N/AShort Interest ↑Gap DownNLSPNLS PharmaceuticsN/A$1.78+0.6%N/A-68.1%$6.34MN/A0.006News CoverageAnalyst ForecastShort Interest ↑CPHIChina Pharma0.1517 of 5 stars$1.88+1.0%N/A-92.3%$6.07M$4.40M0.00250Short Interest ↑ Related Companies and Tools Related Companies Alzamend Neuro Alternatives Soligenix Alternatives Novogen Alternatives Nuvilex Alternatives Polyrizon Alternatives Qualigen Therapeutics Alternatives Sonoma Pharmaceuticals Alternatives Psyence Biomedical Alternatives NLS Pharmaceutics Alternatives China Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTIX) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredBankrupt to billionaire after retirement?Expert Reveals: The #1 Retirement Play for 2025 "We're Entering the Greatest Energy Bull Market Since the I...Brownstone Research | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atrinsic Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atrinsic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.